Pacira Biosciences (PCRX) said Monday it settled the litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals and eVenus Pharmaceuticals Laboratories related to patents for Exparel.
The parties will file consent judgments with the US Court of Appeals for the Federal Circuit and the US District Courts for the Districts of New Jersey and Illinois that enjoin Fresenius from marketing generic bupivacaine liposome injectable suspension before the expiration of the patents-in-suit.
In settlement of all outstanding claims in the litigations, Pacira agreed to provide Fresenius with a license to Pacira's patents to manufacture and sell certain volume-limited amounts of generic bupivacaine liposome injectable suspension in the US beginning on an undisclosed date in early 2030.
The license will permit entry of generic bupivacaine liposome injectable suspension before the July 2, 2044, expiration date of the last-to-expire of Pacira's Orange Book-listed patents for Exparel.
Exparel is a local analgesic used to decrease sensation in a small area post surgery.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。